DK2578590T3 - Anti-inflammatorisk forbindelse med inhibitorisk aktivitet mod flere tyrosinkinaser og farmaceutisk sammensætning indeholdende samme - Google Patents
Anti-inflammatorisk forbindelse med inhibitorisk aktivitet mod flere tyrosinkinaser og farmaceutisk sammensætning indeholdende sammeInfo
- Publication number
- DK2578590T3 DK2578590T3 DK11786920.6T DK11786920T DK2578590T3 DK 2578590 T3 DK2578590 T3 DK 2578590T3 DK 11786920 T DK11786920 T DK 11786920T DK 2578590 T3 DK2578590 T3 DK 2578590T3
- Authority
- DK
- Denmark
- Prior art keywords
- tyrosinkinasas
- inhibitorial
- inflammatory
- relationship
- pharmaceutical composition
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20100049368 | 2010-05-26 | ||
| PCT/KR2010/003332 WO2011149126A1 (ko) | 2010-05-26 | 2010-05-26 | 타이로신 카이네이즈 저해능을 가지는 항염증 화합물을 포함하는 약학적 조성물 |
| PCT/KR2011/003873 WO2011149288A2 (ko) | 2010-05-26 | 2011-05-26 | 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2578590T3 true DK2578590T3 (da) | 2017-11-20 |
Family
ID=45004583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11786920.6T DK2578590T3 (da) | 2010-05-26 | 2011-05-26 | Anti-inflammatorisk forbindelse med inhibitorisk aktivitet mod flere tyrosinkinaser og farmaceutisk sammensætning indeholdende samme |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9062066B2 (da) |
| EP (1) | EP2578590B1 (da) |
| JP (1) | JP5613323B2 (da) |
| KR (1) | KR101478302B1 (da) |
| CN (1) | CN102971327B (da) |
| DK (1) | DK2578590T3 (da) |
| ES (1) | ES2647586T3 (da) |
| HU (1) | HUE035589T2 (da) |
| WO (1) | WO2011149288A2 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10813917B2 (en) * | 2009-12-11 | 2020-10-27 | Medregen, Llc | Treatment methods utilizing stem cell mobilizers and immunosuppressive agents |
| WO2013166295A1 (en) | 2012-05-02 | 2013-11-07 | Georgetown University | Treating neural disease with tyrosine kinase inhibitors |
| KR101540051B1 (ko) * | 2013-11-27 | 2015-07-28 | 한국과학기술연구원 | 피부 노화 방지 또는 피부 상태 개선용 조성물 |
| JP2017527615A (ja) * | 2014-09-02 | 2017-09-21 | シーダーズ−サイナイ メディカル センター | 線維化疾患及び癌を治療するための組成物及び方法 |
| WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
| WO2018081777A1 (en) * | 2016-10-31 | 2018-05-03 | Georgetown University | Compositions and methods for treating neurodegenerative disorders |
| US11426406B2 (en) | 2017-02-09 | 2022-08-30 | Georgetown University | Compositions and methods for treating lysosomal storage disorders |
| JP7629200B2 (ja) | 2018-11-20 | 2025-02-13 | ジョージタウン ユニバーシティ | 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法 |
| CN110368498A (zh) * | 2019-08-26 | 2019-10-25 | 瑞希(重庆)生物科技有限公司 | 一种促进伤口愈合的制剂及其制备方法 |
| WO2024096569A1 (ko) * | 2022-11-02 | 2024-05-10 | 주식회사 지와이생명과학 | 싸이에노피리딘 화합물을 포함하는 경피 또는 국소 투여용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309690A1 (en) * | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| DE602005018972D1 (de) * | 2005-09-23 | 2010-03-04 | Equispharm Co Ltd | 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren |
| US20070213305A1 (en) * | 2005-11-02 | 2007-09-13 | Cytovia, Inc. | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| KR101126736B1 (ko) * | 2008-11-27 | 2012-04-12 | 주식회사 레고켐 바이오사이언스 | 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물 |
-
2011
- 2011-05-26 KR KR1020127030670A patent/KR101478302B1/ko active Active
- 2011-05-26 EP EP11786920.6A patent/EP2578590B1/en active Active
- 2011-05-26 US US13/699,970 patent/US9062066B2/en active Active
- 2011-05-26 HU HUE11786920A patent/HUE035589T2/en unknown
- 2011-05-26 WO PCT/KR2011/003873 patent/WO2011149288A2/ko not_active Ceased
- 2011-05-26 DK DK11786920.6T patent/DK2578590T3/da active
- 2011-05-26 CN CN201180026042.7A patent/CN102971327B/zh active Active
- 2011-05-26 JP JP2013512543A patent/JP5613323B2/ja active Active
- 2011-05-26 ES ES11786920.6T patent/ES2647586T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130072482A1 (en) | 2013-03-21 |
| HUE035589T2 (en) | 2018-05-28 |
| JP5613323B2 (ja) | 2014-10-22 |
| EP2578590B1 (en) | 2017-08-16 |
| KR20130031266A (ko) | 2013-03-28 |
| WO2011149288A2 (ko) | 2011-12-01 |
| KR101478302B1 (ko) | 2014-12-31 |
| ES2647586T3 (es) | 2017-12-22 |
| EP2578590A4 (en) | 2013-12-04 |
| CN102971327B (zh) | 2016-04-20 |
| JP2013527199A (ja) | 2013-06-27 |
| CN102971327A (zh) | 2013-03-13 |
| EP2578590A2 (en) | 2013-04-10 |
| WO2011149288A3 (ko) | 2012-04-19 |
| US9062066B2 (en) | 2015-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2578590T3 (da) | Anti-inflammatorisk forbindelse med inhibitorisk aktivitet mod flere tyrosinkinaser og farmaceutisk sammensætning indeholdende samme | |
| HRP20160579T1 (hr) | Spoj indola i njegova farmaceutska upotreba | |
| SMT201700008B (it) | Composizione farmaceutica | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| DK2648742T3 (da) | Formuleringer indeholdende saponiner og anvendelser deraf | |
| DK3175711T3 (da) | Parasitiske sammensætninger indeholdende multiple aktivstoffer, fremgangsmåder og anvendelser deraf | |
| ZA201300920B (en) | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same | |
| SI3246018T1 (sl) | Farmacevtski sestavek | |
| EP2771321A4 (en) | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH | |
| PL2704703T3 (pl) | Transdermalne kompozycje ibuprofenu i sposoby ich stosowania | |
| EP2616076A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| DK2729151T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| EP2647381A4 (en) | MELTING TABLET | |
| ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
| HRP20170936T1 (hr) | Alkilamido spojevi i njihova uporaba | |
| SI2645992T1 (sl) | Trdna oralna dozirna oblika z asimetrično obliko | |
| DK2542224T3 (da) | Oral farmaceutisk sammensætning indeholdende dabigatranetexilat | |
| PL2651409T3 (pl) | Nowa kompozycja farmaceutyczna zawierająca nlpz i cyklodekstrynę | |
| EP2474522A4 (en) | AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| DK2475649T3 (da) | Indenonderivat og farmaceutisk sammensætning omfattende samme | |
| DK2642992T3 (da) | Forbindelser og anvendelse deraf | |
| EP2685993A4 (en) | PHARMACEUTICAL COMPOSITIONS AND TOPICAL USE THEREOF |